NZ593223A - 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1 (2,6).1(8, 12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt - Google Patents

11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1 (2,6).1(8, 12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt

Info

Publication number
NZ593223A
NZ593223A NZ593223A NZ59322309A NZ593223A NZ 593223 A NZ593223 A NZ 593223A NZ 593223 A NZ593223 A NZ 593223A NZ 59322309 A NZ59322309 A NZ 59322309A NZ 593223 A NZ593223 A NZ 593223A
Authority
NZ
New Zealand
Prior art keywords
heptacosa
dioxa
pyrrolidin
ethoxy
citrate salt
Prior art date
Application number
NZ593223A
Other languages
English (en)
Inventor
Cheng Hsia Angeline Lee
Anthony Deodaunia William
Brian Dymock
Original Assignee
Cell Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Therapeutics Inc filed Critical Cell Therapeutics Inc
Publication of NZ593223A publication Critical patent/NZ593223A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/22—Tricarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D201/00—Preparation, separation, purification or stabilisation of unsubstituted lactams
    • C07D201/02—Preparation of lactams
    • C07D201/10—Preparation of lactams from cycloaliphatic compounds by simultaneous nitrosylation and rearrangement
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
NZ593223A 2008-12-11 2009-12-09 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1 (2,6).1(8, 12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt NZ593223A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12166808P 2008-12-11 2008-12-11
PCT/SG2009/000473 WO2010068181A1 (en) 2008-12-11 2009-12-09 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27)j16,21,23-decaene citrate salt

Publications (1)

Publication Number Publication Date
NZ593223A true NZ593223A (en) 2013-08-30

Family

ID=41666397

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ593223A NZ593223A (en) 2008-12-11 2009-12-09 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1 (2,6).1(8, 12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt

Country Status (23)

Country Link
US (2) US8980873B2 (enExample)
EP (1) EP2376499B1 (enExample)
JP (1) JP5669748B2 (enExample)
KR (1) KR101729918B1 (enExample)
CN (1) CN102282148B (enExample)
AR (2) AR074724A1 (enExample)
AU (1) AU2009325147B2 (enExample)
BR (1) BRPI0922736B1 (enExample)
CA (1) CA2746058C (enExample)
DK (1) DK2376499T3 (enExample)
ES (1) ES2536558T3 (enExample)
HR (1) HRP20150428T1 (enExample)
IL (3) IL213418A0 (enExample)
MX (1) MX2011006206A (enExample)
MY (1) MY160005A (enExample)
NZ (1) NZ593223A (enExample)
PL (1) PL2376499T3 (enExample)
PT (1) PT2376499E (enExample)
RU (1) RU2527970C2 (enExample)
SG (1) SG171907A1 (enExample)
TW (1) TWI449705B (enExample)
WO (1) WO2010068181A1 (enExample)
ZA (1) ZA201104032B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011006206A (es) 2008-12-11 2011-07-20 S Bio Pte Ltd Sal de citrato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26- triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5 ,8,10,12(27),16,21,23-decaeno.
EP2376500B1 (en) * 2008-12-11 2015-02-25 Cti Biopharma Corp. 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene maleate salt
PL2837632T3 (pl) 2012-04-13 2017-01-31 Lianyungang Jinkang Hexin Pharmaceutical Co. Ltd. Pochodne triazabicyklo[3.2.1]oktanu użyteczne do leczenia chorób proliferacyjnych
CN105061467B (zh) * 2015-08-28 2017-08-25 苏州立新制药有限公司 一种帕克替尼的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728536A (en) 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
US6136595A (en) 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
HRP20030911A2 (en) * 2001-05-14 2004-02-29 Pfizer Prod Inc Citrate salt 5,8,14,-triazatetracyclo (10.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>)-hexadeca-2 (11), 3,5,7,9-pentaene
US6433018B1 (en) 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
KR20040066140A (ko) * 2001-11-29 2004-07-23 화이자 프로덕츠 인크. 5,8,14-트리아자테트라시클로[10.3.1.0(2,11).0(4,9)]헥사데카-2(11),3,5,7,9-펜타엔의 숙신산염 및 그의 제약 조성물
CN101365703B (zh) * 2005-11-16 2013-11-06 S*Bio私人有限公司 杂烷基连接的嘧啶衍生物
MX2011006206A (es) 2008-12-11 2011-07-20 S Bio Pte Ltd Sal de citrato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26- triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5 ,8,10,12(27),16,21,23-decaeno.

Also Published As

Publication number Publication date
CN102282148A (zh) 2011-12-14
PL2376499T3 (pl) 2015-07-31
WO2010068181A8 (en) 2011-08-18
EP2376499A1 (en) 2011-10-19
BRPI0922736B1 (pt) 2022-02-22
CA2746058A1 (en) 2010-06-17
AR114133A2 (es) 2020-07-22
AU2009325147A1 (en) 2011-06-23
SG171907A1 (en) 2011-07-28
ES2536558T3 (es) 2015-05-26
TW201028426A (en) 2010-08-01
BRPI0922736A2 (pt) 2017-10-31
RU2011126173A (ru) 2013-01-20
PT2376499E (pt) 2015-06-03
MX2011006206A (es) 2011-07-20
AR074724A1 (es) 2011-02-09
IL250310A0 (en) 2017-03-30
US20110294831A1 (en) 2011-12-01
IL289379A (en) 2022-02-01
CN102282148B (zh) 2014-12-24
AU2009325147B2 (en) 2014-08-14
CA2746058C (en) 2016-05-17
DK2376499T3 (en) 2015-05-04
JP5669748B2 (ja) 2015-02-12
IL213418A0 (en) 2011-07-31
WO2010068181A1 (en) 2010-06-17
HK1161877A1 (en) 2012-08-10
HRP20150428T1 (xx) 2015-06-19
JP2012511571A (ja) 2012-05-24
RU2527970C2 (ru) 2014-09-10
US9624242B2 (en) 2017-04-18
KR20110106344A (ko) 2011-09-28
KR101729918B1 (ko) 2017-04-25
ZA201104032B (en) 2012-08-29
US20150322084A1 (en) 2015-11-12
BRPI0922736A8 (pt) 2021-11-09
MY160005A (en) 2017-02-15
TWI449705B (zh) 2014-08-21
EP2376499B1 (en) 2015-02-25
US8980873B2 (en) 2015-03-17

Similar Documents

Publication Publication Date Title
WO2010026436A3 (en) 1,3, 4, 6, 7, 11b-hexahydro-benzo[alpha]quinolizines for the treatment of hyperkinetic movement and related disorders
SG164378A1 (en) Compounds for the treatment of proliferative disorders
MY174452A (en) Substituted piperidines that increase p53 activity and the uses thereof
WO2009050228A3 (en) Csf-1r inhibitors for treatment of cancer and bone diseases
WO2008044243A3 (en) Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof
MX2012001420A (es) Derivados de pirrolo[1,2-b]piridazina como inhibidores de cinasa janus.
MY139399A (en) Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
NZ578697A (en) Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
MX2009012168A (es) Derivados de pirrolopiridina y su uso como inhibidores de la enzima que escinde la proteina precursora de amiloide por el sitio beta.
MXPA05010712A (es) Derivados de quinolin-2-ona para el tratamiento de enfermedades de las vias respiratorias.
MX2010003868A (es) Cis-imidazolinas quirales.
TW200800990A (en) Azaindole inhibitors of aurora kinases
UA89123C2 (ru) Производные пиримидина для лечения абнормального роста клеток
TN2012000248A1 (en) Novel spiropiperidine compounds
MY139902A (en) Crystalline form v of agomelatine, a process for its preparation and pharmaceutical compositions containing it
TW200806282A (en) Solid dosage formulations
WO2011023367A3 (en) Bisphosphonate-prodrugs
WO2009047775A3 (en) Polymorphs of esomeprazole salts
JO3360B1 (ar) الشكل البلوري الجديد 3 للأغوميلاتين وعملية تحضيره والمكونات الصيدلانية التي تحتويه
TW200716570A (en) Compounds for the treatment of proliferative disorders
WO2006104668A3 (en) Composition and methods for the treatment of proliferative diseases
UA89905C2 (ru) α КРИСТАЛЛИЧЕСКАЯ ФОРМА АРГИНИНОВОЙ СОЛИ ПЕРИНДОПРИЛА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ЕЕ СОДЕРЖИТ
NZ593223A (en) 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1 (2,6).1(8, 12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
IL266097B (en) &#34; a mono-orotate acid addition salt of (r)-5-((e)-2-pyrrolidin-3-ylvinyl)pyrimidine”
WO2008038092A3 (en) Substituted piperidinophenyl oxazolidinones

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: CELL THERAPEUTICS, US

Free format text: OLD OWNER(S): S*BIO PTE LTD

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 09 DEC 2016 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20140317

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 DEC 2017 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20161125

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 DEC 2018 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20171127

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 DEC 2019 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20181121

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 DEC 2020 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20191126

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 DEC 2021 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20201102

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 DEC 2022 BY COMPUTER PACKAGES INC

Effective date: 20211117

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 DEC 2023 BY CPA GLOBAL

Effective date: 20221027

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 DEC 2024 BY CPA GLOBAL

Effective date: 20231026

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 DEC 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20241101

ASS Change of ownership

Owner name: SOBI, INC., US

Effective date: 20250911

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 DEC 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20251025